Application of Medicinal Plants to Cure Mental Disorders


Year : 2024 | Volume : 14 | Issue : 01 | Page : 69-78
    By

    Sankalp Tikku,

  • Uday Kapur,

  • Pankaj Kumar Tripathi,

  • Chakresh Kumar Jain,

  1. Student, Department of Biotechnology, Jaypee Institute of Information Technology, Noida, Uttar Pradesh, India
  2. Student, Department of Biotechnology, Jaypee Institute of Information Technology, Noida, Uttar Pradesh, India
  3. Research Scholar, Department of Biotechnology, Jaypee Institute of Information Technology, Noida, Uttar Pradesh, India
  4. Associate Professor, Department of Biotechnology, Jaypee Institute of Information Technology, Noida, Uttar Pradesh, India

Abstract

Mental fitness is a state of well-being in which individuals apprehend their talents, manage existing pressures, remain efficient, and contribute to their groups. Mental contamination regularly used interchangeably with intellectual illness, is vital to apprehending and addressing man or woman desires and challenges. Schizophrenia, a psychological disorder characterized by hallucinations and delusions, is a complex situation with two important classes: bad symptoms (withdrawal from social interactions, loss of force, and unresponsive emotional country) and high-quality signs and symptoms (hallucinations, delusions, and disordered thoughts). India has a large and diversified population, which contributes to a significant mental health burden that needs immediate treatment. Mental health illnesses affect people from all walks of life and transcend age, financial status, and geographic location. These disorders have a wide range of consequences, including increased society expenses, diminished everyday functioning, and personal misery. The increasing public health concern is a result of the steady growth in the prevalence of mental health diseases in India in recent years. It is estimated that around 15% of Indians suffer from mental health problems. Numerous conditions are included in this figure, such as substance use disorders, anxiety disorders, depression, bipolar disorder, schizophrenia, and neurodevelopmental disorders. Medicinal plants have vast potential in healthcare worldwide, mainly in growing international locations where 70-80% of people depend on traditional medication for primary healthcare wishes. These flowers of er a desire for novel remedies for drug-resistant diseases and ailments left unaddressed by mainstream prescription medications. Traditional healers have used several plant lives with validated healing blessings, consisting of natural remedies incorporated into psychiatry for intellectual ailments like schizophrenia. Phytochemicals determined in vegetation can enhance the features of diverse human organs, preventing many diseases. Many traditional medicinal herbs and their components have healing properties and may be used to save you, deal with, or cure diverse human sicknesses.

Keywords: Medicinal Plants, Mental Disorders, Antipsychotic plants, Depression, Anxiety, Schizophrenia, Epilepsy, Neuralgia

[This article belongs to Research & Reviews : A Journal of Biotechnology (rrjobt)]

How to cite this article:
Sankalp Tikku, Uday Kapur, Pankaj Kumar Tripathi, Chakresh Kumar Jain. Application of Medicinal Plants to Cure Mental Disorders. Research & Reviews : A Journal of Biotechnology. 2024; 14(01):69-78.
How to cite this URL:
Sankalp Tikku, Uday Kapur, Pankaj Kumar Tripathi, Chakresh Kumar Jain. Application of Medicinal Plants to Cure Mental Disorders. Research & Reviews : A Journal of Biotechnology. 2024; 14(01):69-78. Available from: https://journals.stmjournals.com/rrjobt/article=2024/view=143851


References

1. Aljunaidy MM, Adi MN. Architecture and mental disorders: A systematic study of peer-reviewed literature. HERD. 2020;13(4):320-330. DOI: 10.1177/1937586720973767.
2. Hernández-Torrano D, Ibrayeva L, Sparks J, Lim N, Clementi A, Almukhambetova A, et al. Mental health and well-being of university students: A bibliometric mapping of the literature. Front Psychol. 2020;11:1226. DOI: 10.3389/fpsyg.2020.01226.
3. World Health Organization (WHO). Depression and other common mental disorders: Global health estimates. 2022.
4. Allen N. Book review: Cognitive therapy of depression. Aust N Z J Psychiatry. 2002;36(2):275-278. DOI: 10.1046/j.1440-1614.2002.t01-5-01015.x.
5. Ellsworth PD. Diagnostic and statistical manual of mental disorder. Am J Occup Ther. 1980;34(12):819. DOI: 10.5014/ajot.34.12.819a.
6. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358(1):55-68. DOI: 10.1056/nejmra073096.
7. Eylem Ö, De Wit L, Van Straten A, Steubl L, Melissourgaki Z, Danışman GT, et al. Stigma for common mental disorders in racial minorities and majorities: A systematic review and meta-analysis. BMC Public Health. 2020;20:869. DOI: 10.1186/s12889-020-08964-3.
8. Moshiri E, Basti AA, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: A double-blind, randomized and placebo-controlled trial. Phytomedicine. 2006;13(9-10):607-611. DOI: 10.1016/j.phymed.2006.08.006.
9. Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, Amini H, Fallah-Pour H, Jamshidi AH, et al. Crocus sativus L. in the treatment of mild to moderate depression: A double‐blind, randomized and placebo‐controlled trial. Phytother Res. 2005;19(2):148-151. DOI: 10.1002/ptr.1647.
10. Basti AA, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: A pilot double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):439-442. DOI: 10.1016/j.pnpbp.2006.11.010.
11. Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH, Khalighi-Cigaroudi F. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: A pilot double-blind randomized trial [ISRCTN45683816]. BMC Complement Altern Med. 2004;4:12. DOI: 10.1186/1472-6882-4-12.
12. Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: A double-blind, randomized pilot trial. J Ethnopharmacol. 2005;97(2):281-284. DOI: 10.1016/j.jep.2004.11.004.
13. Hausenblas HA, Saha D, Dubyak PJ, Anton SD. Saffron (Crocus sativus L.) and major depressive disorder: A meta-analysis of randomized clinical trials. J Integr Med. 2013;11(5):377-383. DOI: 10.3736/jintegrmed2013056.
14. Lopresti AL, Drummond PD. Saffron (Crocus sativus) for depression: A systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Hum Psychopharmacol. 2014;29(6):517-527. DOI: 10.1002/hup.2434.
15. Mazidi M, Shemshian M, Mousavi SH, Norouzy A, Kermani T, Moghiman T, et al. A double-blind, randomized and placebo-controlled trial of saffron (Crocus sativus L.) in the treatment of anxiety and depression. J Complement Integr Med. 2016;13(3):195-199. DOI: 10.1515/jcim-2015-0043.
16. Teschke R, Gaus W, Loew D. Kava extracts: Safety and risks including rare hepatotoxicity. Phytomedicine. 2003;10(7):440-446. DOI: 10.1078/0944-7113-00314.
17. Pantano F, Tittarelli R, Mannocchi G, Zaami S, Ricci S, Giorgetti R, et al. Hepatotoxicity induced by “the 3Ks”: Kava, kratom and khat. Int J Mol Sci. 2016;17(4):580. DOI: 10.3390/ijms17040580.
18. Abolhassani M. Clinical research antiviral activity of borage (Echium amoenum). Arch Med Sci. 2010;6(3):366-369. DOI: 10.5114/aoms.2010.14256.
19. Sayyah M, Sayyah M, Kamalinejad M. A preliminary randomized double-blind clinical trial on the efficacy of aqueous extract of Echium amoenum in the treatment of mild to moderate major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(1):166-169. DOI: 10.1016/j.pnpbp.2005.10.005.
20. D K, Suresh K. Screening of antianxiety activity of Abies pindrow Royle aerial parts. Indian J Pharm Educ Res. 2015. http://dx.doi.org/10.5530/ijper.49.1.9.
21. Anita R, Chander M. Pharmacological and phytochemical evaluation of Calendula officinalis Linn. for anti-anxiety activity. Int J Pharm Phytochem Res. 2017;9(1):1-8. DOI: 10.25258/ijpapr.v9i1.8051.
22. Kaur D, Shri R, Kamboj A. Evaluation of anti-anxiety effect of Brassica oleracea L. extracts in experimental animals. Pharmacogn J. 2017;9(5):638-643. DOI: 10.5530/pj.2017.5.101.
23. World Health Organization (WHO). Schizophrenia. 2022. https://www.who.int/news-room/fact-sheets/detail/schizophrenia#:~:text=Schizophrenia%20affects%20approximately%2024%20million,as%20many%20other%20mental%20disorders.
24. Charlson FJ, Ferrari AJ, Santomauro D, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: Findings from the global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195-1203. DOI: 10.1093/schbul/sby058.
25. Rajalakshmi R, Menon KN, Nair SC. Nanotechnology approaches for enhanced CNS drug delivery in the management of schizophrenia. Adv Pharm Bull. 2021;11(3):490-508. DOI: 10.34172/apb.2022.052.
26. Rathbone J, Zhang L, Zhang M, Xia J, Liu X, Yang Y. Chinese herbal medicine for schizophrenia. Cochrane Database Syst Rev. 2005;(4). DOI: 10.1002/14651858.CD003444.pub2.
27. Xiao S, Han X, Li X, Chen C, Li G, Yuan C, et al. A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. Neurosci Bull. 2011;27(4):258-268. DOI: 10.1007/s12264-011
28. Deng H, Adams CE. Traditional Chinese medicine for schizophrenia: A survey of randomized trials. Asia-Pac Psychiatry. 2016;9. DOI: 10.1111/appy.12265.
29. Shorvon S. The causes of epilepsy: Changing concepts of etiology of epilepsy over the past 150 years. Epilepsia. 2011;52(6):1033-44. DOI: 10.1111/j.1528-1167.2011.03051.x.
30. Wa H. Epilepsy: frequency, causes and consequences. CiNii Res. 1990. https://cir.nii.ac.jp/crid/1572543024619962880.
31. Stafstrom CE, Carmant L. Seizures and epilepsy: An overview for neuroscientists. Cold Spring Harb Perspect Med. 2015;5(6). DOI: 10.1101/cshperspect.a022426.
32. Pahuja M, Mehla J, Reeta KH, Joshi S, Gupta YK. Hydroalcoholic extract of Zizyphus jujuba ameliorates seizures, oxidative stress, and cognitive impairment in experimental models of epilepsy in rats. Epilepsy Behav. 2011;22(3):356-63. DOI: 10.1016/j.yebeh.2011.05.013.
33. Pahuja M, Kleekal T, Reeta KH, Tripathi M, Gupta YK. Interaction profile of Zizyphus jujuba with phenytoin, phenobarbitone, and carbamazepine in maximal electroshock-induced seizures in rats. Epilepsy Behav. 2012;24(3):368-73. DOI: 10.1016/j.yebeh.2012.08.014.
34. Ahmad B. Distribution, morphology, and medicinal uses of Taxus baccata. DeptOZ. 1997. https://agris.fao.org/search/en/providers/122650/records/6472305f53aa8c896301d8a5.
35. Nisar M, Khan I, Simjee SU, Gilani AH, Obaidullah, Perveen H. Anticonvulsant, analgesic, and antipyretic activities of Taxus wallichiana Zucc. J Ethnopharmacol. 2008;116(3):490-4. DOI: 10.1016/j.jep.2007.12.021.
36. Wang S, Li X, Zhou S, Sun DX, Wang H, Cheng P, et al. Intervention effects of Ganoderma lucidum spores on epileptiform discharge hippocampal neurons and expression of neurotrophin-4 and N-cadherin. PLoS One. 2013;8(4). DOI: 10.1371/journal.pone.0061687.
37. Socała K, Nieoczym D, Grzywnowicz K, Stefaniuk D, Właź P. Evaluation of anticonvulsant, antidepressant-, and anxiolytic-like effects of an aqueous extract from cultured mycelia of the Lingzhi or Reishi medicinal mushroom Ganoderma lucidum (Higher Basidiomycetes) in mice. Int J Med Mushrooms. 2015;17(3):209-18. DOI: 10.1615/intjmedmushrooms.v17.i3.10.
38. Tello I, Campos-Peña V, Montiel E, Rodríguez V, Aguirre-Moreno A, León-Rivera I, et al. Anticonvulsant and neuroprotective effects of oligosaccharides from Lingzhi or Reishi medicinal mushroom, Ganoderma lucidum (Higher Basidiomycetes). Int J Med Mushrooms. 2013;15(6):555-68. DOI: 10.1615/intjmedmushr.v15.i6.40.
39. Wang S, Li X, Qiu H, Jiang Z, Simon M, Ma X, et al. Anti-epileptic effect of Ganoderma lucidum polysaccharides by inhibition of intracellular calcium accumulation and stimulation of expression of CaMKII α in epileptic hippocampal neurons. PLoS One. 2014;9(7). DOI: 10.1371/journal.pone.0102161.
40. MacLaren R, Forrest LK, Kiser TH. Adjunctive dexmedetomidine therapy in the intensive care unit: A retrospective assessment of impact on sedative and analgesic requirements, levels of sedation and analgesia, and ventilatory and hemodynamic parameters. Pharmacotherapy. 2007;27(3):351-9. DOI: 10.1592/phco.27.3.351.
41. Zakrzewska JM, McMillan R. Trigeminal neuralgia: The diagnosis and management of this excruciating and poorly understood facial pain. Postgrad Med J. 2011;87(1028):410-6. DOI: 10.1136/pgmj.2009.080473.
42. Cruccu G, Gronseth GS, Alksne JF, Argoff CE, Brainin M, Burchiel KJ, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15(10):1013-28. DOI: 10.1111/j.1468-1331.2008.02185.x.
43. Emril DR, Ho KL. Treatment of trigeminal neuralgia: Role of radiofrequency ablation. J Pain Res. 2010;3:249-54. DOI: 10.2147/jpr.s14455.
44. Pollock BE. Surgical management of medically refractory trigeminal neuralgia. Curr Neurol Neurosci Rep. 2011;11(2):125-31. DOI: 10.1007/s11910-011-0242-7.
45. Muthuraman A, Singh N, Jaggi AS. Effect of hydroalcoholic extract of Acorus calamus on tibial and sural nerve transection-induced painful neuropathy in rats. J Nat Med. 2010;64(3):282-92. DOI: 10.1007/s11418-010-0486-6.
46. Watcho P, Stavniichuk R, Ribnicky DM, Raskin I, Obrosova IG. High-fat diet-induced neuropathy of prediabetes and obesity: Effect of PMI-5011, an ethanolic extract of Artemisia dracunculus L. Mediators Inflamm. 2010;2010:268547. DOI: 10.1155/2010/268547.
47. Hong JH, Lee IS. Effects of Artemisia capillaris ethyl acetate fraction on oxidative stress and antioxidant enzyme in high-fat diet-induced obese mice. Chem Biol Interact. 2009;179(1):88-93. DOI: 10.1016/j.cbi.2008.12.002.
48. Reza SM, Mirshekari H, Saberi Z. The nociceptive and anti-inflammatory effects of Artemisia dracunculus L. aqueous extract on fructose-fed male rats. Evid Based Complement Alternat Med. 2015;2015:895417. DOI: 10.1155/2015/895417.
49. Thiagarajan VRK, Shanmugam P, Krishnan UM, Muthuraman A, Singh N. Antinociceptive effect of Butea monosperma on vincristine-induced neuropathic pain model in rats. Toxicol Ind Health. 2012;28(1):3-13. DOI: 10.1177/0748233711432573.
50. Thiagarajan VRK, Shanmugam P, Krishnan UM, Muthuraman A, Singh N. Ameliorative potential of Butea monosperma on chronic constriction injury of the sciatic nerve induced neuropathic pain in rats. An Acad Bras Cienc. 2012;84(4):1091-104. DOI: 10.1590/s0001-37652012005000063.
51. Zhou J, Ouédraogo M, Qu F, Duez P. Potential genotoxicity of traditional Chinese medicinal plants and phytochemicals: An overview. Phytother Res. 2013;27(12):1745-55. DOI: 10.1002/ptr.4942.
52. Rodrigues E, Barnes J. Pharmacovigilance of herbal medicines. Drug Saf. 2012;35(1):1-12. DOI: 10.1007/s40264-012-0005-7.
53. Farah MH, Edwards IR, Lindquist M, Shaw D. International monitoring of adverse health effects associated with herbal medicines. Pharmacoepidemiol Drug Saf. 2000;9(2):105-12. DOI: 10.1002/(sici)1099-1557(200003/04)9:
54. Chaudhari V, Pinjari P, Patil P, Khandare S, Salunke R. Future prospects of medicinal plants. Int J Pharm Res Appl. 2022;7(3):1816-22.


Regular Issue Subscription Review Article
Volume 14
Issue 01
Received 28/03/2024
Accepted 13/04/2024
Published 09/05/2024